Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20935616 | 0.77 | KDM4E (0.33) | ADRA2AADRA2BADRA2C | |
| SCHEMBL21536559 | 0.77 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL21536602 | 0.77 | GRM5 (0.46) | — | |
| SCHEMBL22270434 | 0.75 | ADRA2A (0.41) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL23627445 | 0.74 | NOS3 (0.30) | — | |
| SCHEMBL18467799 | 0.73 | KDM4E (0.41) | — | |
| SCHEMBL1137069 | 0.71 | ADRA2A (0.37) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL29350657 | 0.71 | ADRA2A (0.37) | DRD2DRD4DRD3CA12CA1 | |
| SCHEMBL26178491 | 0.69 | — | — | |
| SCHEMBL22911966 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617222-B1 | Alkynyl indazole derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096400-A1 | ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | DRD2 3250/4885DRD4 3350/4885DRD3 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.